Hypertension
Adult: 2-4 mg once daily.
Oral
Oedema
Adult: Initially, 1-4 mg once daily in the morning.
Indications and Dosage
Oral
Hypertension Adult: 2-4 mg once daily. Oral Oedema Adult: Initially, 1-4 mg once daily in the morning.
|
Contraindications
Hypersensitivity to sulfonamide-derived drugs, anuria.
|
Special Precautions
Patient w/ fluid and electrolyte imbalance, history of bronchial asthma, gout, DM. May exacerbate SLE. Hepatic and renal impairment. Pregnancy and lactation.
|
Adverse Reactions
Anorexia, gastric irritation, nausea, vomiting, cramping, diarrhoea, constipation, jaundice, pancreatitis, dizziness, vertigo, paraesthesias, headache, xanthopsia, leukopenia, agranulocytosis, thrombocytopenia, aplastic anaemia, purpura, photosensitivity, rash, urticaria, necrotising angiitis, orthostatic hypotension, electrolyte imbalance, hyperglycaemia, glycosuria, hyperuricaemia, muscle spasm, weakness, restlessness.
|
Monitoring Parameters
Determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.
|
Drug Interactions
May increase the risk of lithium toxicity. Hypokalaemia may develop w/ concomitant use of corticosteroids or ACTH. May augment the paralyzing actions of tubocurarine and decrease arterial responsiveness to norepinephrine. May alter antidiabetic dosing. Orthostatic hypotension may be aggravated w/ barbiturates or narcotics. Metabolic effects of hypokalaemia may be increased w/ concomitant digitalis therapy.
|
Lab Interference
May alter laboratory test results for K, BUN, glucose, and protein-bound iodine (PBI).
|
Action
Description:
Mechanism of Action: Polythiazide reduces the reabsorption of electrolytes from the renal tubules, thereby increasing the excretion of Na and Cl ions and consequently of water. It also reduces the GFR. Onset: Approx 2 hr. Duration: 24-48 hr. Pharmacokinetics: Absorption: Readily absorbed from the GI tract. Distribution: Plasma protein binding: >80%. Excretion: Via urine (as unchanged drug) and faeces. Elimination half-life: Approx 26 hr. |
Storage
Store between 20-25°C.
|
MIMS Class
|
References
Buckingham R (ed). Polythiazide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/06/2014. McEvoy GK, Snow EK, Miller J et al (eds). Polythiazide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 02/06/2014. Renese Tablet (Pfizer Labs). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/06/2014.
|